跛行患者外周血管内介入术后治疗性抗凝的结局
基于血管质量倡议(VQI)2010—2019年因跛行行首次外周血管内介入(PVI)的26240例患者,9.1%出院时接受抗凝治疗。倾向评分逆概率加权分析显示,任何抗凝与全因死亡风险升高相关(aHR 1.61,95%CI 1.35-1.92),维生素K拮抗剂与通畅丧失、主要不良肢体事件(MALE)和死亡风险升高相关,口服Xa因子抑制剂与通畅丧失风险降低相关但死亡风险升高。
要点
- PVI后任何抗凝与全因死亡风险升高相关(aHR 1.61,95%CI 1.35-1.92)。
- 维生素K拮抗剂与通畅丧失(aHR 1.32)、MALE(aHR 1.33)和死亡(aHR 1.46)风险升高相关。
- 口服Xa因子抑制剂与通畅丧失风险降低相关(aHR 0.61),但死亡风险升高(aHR 1.51)。
核心结论
- PVI后治疗性抗凝与全因死亡风险升高相关。
- 口服Xa因子抑制剂与通畅丧失风险降低相关,而维生素K拮抗剂与通畅丧失、MALE和死亡风险升高相关。
- 需要进一步的前瞻性研究来探讨PVI后全剂量抗凝的安全性和有效性。
研究设计与样本
- 利用血管质量倡议(Vascular Quality Initiative)数据库,纳入2010—2019年因跛行行首次PVI的患者26240例。
- 按出院时是否使用抗凝药进行分层,9.1%的患者出院时接受抗凝药。
- 构建倾向评分调整合并症,并采用逆概率加权估计抗凝与结局的关联。
- 主要结局为2年通畅率、主要不良肢体事件(MALE)和死亡。
主要发现
- 接受任何抗凝的患者死亡风险显著升高(aHR 1.61,95%CI 1.35-1.92),但MALE和通畅丧失风险无显著差异。
- 接受维生素K拮抗剂的患者通畅丧失风险显著升高(aHR 1.32,95%CI 1.09-1.60),MALE风险显著升高(aHR 1.33,95%CI 1.13-1.57),死亡风险显著升高(aHR 1.46,95%CI 1.27-1.69)。
- 接受口服Xa因子抑制剂的患者通畅丧失风险显著降低(aHR 0.61,95%CI 0.41-0.93),但死亡风险显著升高(aHR 1.51,95%CI 1.19-1.92)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要进一步的前瞻性研究来探讨PVI后全剂量抗凝的安全性和有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Antiplatelet agents are commonly used after peripheral endovascular intervention (PVI). However, the effect of full-dose anticoagulation on outcomes after PVI is not well-established. We sought to investigate whether full-dose anticoagulation after PVI is associated with adverse events. METHODS: We utilized the Vascular Quality Initiative to study patients undergoing index PVI for claudication (2010-2019), stratified by the presence or absence of an anticoagulant on discharge. The primary outcomes were 2-year patency, major adverse limb events (MALE), and mortality. We built a propensity score adjusting for comorbidities and employed inverse probability weighting to estimate the association of anticoagulation with outcomes. RESULTS: We identified 26,240 patients; 9.1% were discharged on an anticoagulant. Patients receiving any anticoagulation had a significantly higher risk of mortality (adjusted hazard ratio [aHR], 1.61; 95% confidence interval [CI], 1.35-1.92), but not MALE, or patency loss. Patients receiving a vitamin K antagonist had a significantly higher risk of patency loss (aHR, 1.32; 95% CI, 1.09-1.60), MALE (aHR, 1.33; 95% CI, 1.13-1.57), and mortality (aHR, 1.46; 95% CI, 1.27-1.69). Patients on an oral Factor Xa inhibitors had a significantly lower risk of patency loss (aHR, 0.61; 95% CI, 0.41-0.93) but increased mortality (aHR, 1.51; 95% CI, 1.19-1.92). CONCLUSIONS: Therapeutic anticoagulation after PVI is associated with higher risk of all-cause mortality. Although oral Factor Xa inhibitors are associated with decreased risk of patency loss, vitamin K antagonists are associated with higher risk of patency loss, MALE, and death. Further prospective studies are necessary to study the safety and efficacy of full-dose anticoagulation after PVI.
引用
- Lee C, Ramkumar N, Young MN, et al. Therapeutic anticoagulation after index peripheral endovascular intervention in patients with claudication. J Vasc Surg. 2023. PMID: 37579865. doi:10.1016/j.jvs.2023.08.099
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。